Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elo-Pom-Dex With Second ASCT for Relapsed Multiple Myeloma
NCT03030261Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2017
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Molecular Glues
- Countries
- 2
01
Overview
A Phase 2 trial of elotuzumab, pomalidomide in multiple myeloma (MM), sponsored by Washington University School of Medicine. Started Nov 2017; status: active, not recruiting.
02
Drugs
elotuzumabpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03030261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030261.